Vera Therapeutics Inc (NASDAQ: VERA) Stock In Prove Me State

Woodline Partners LP has recently announced that it has increased stake in Vera Therapeutics Inc (NASDAQ:VERA) by 46.13%. After grabbing 2.56 million shares, the institutional investor is now in possession of 0.81 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 5.77% having worth around $39.41 million. Moreover, BlackRock Fund Advisors increased its share by 0.15 million to have a control over 2.14 million shares. And SSgA Funds Management, Inc. raised its holdings to 1.15 million shares by acquiring 1.73 million shares or 3.89% of the stake.

Vera Therapeutics Inc (VERA) concluded trading on Thursday at a closing price of $25.31, with 11.48 million shares of worth about $290.44 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 56.43% during that period and on Thursday, January 25 the price saw a gain of about 48.71%. Currently the company’s common shares owned by public are about 44.43M shares, out of which, 28.13M shares are available for trading.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 30 times over the past 12 months. They bought 4,803,643 shares in 27 of the transactions. In 3 selling transactions, insiders dumped 8,190 shares.

SPDR S&P Biotech ETF, iShares Russell 2000 ETF, and Biotech Growth Trust Plc are the top 3 mutual funds which are holding stakes in Vera Therapeutics Inc SPDR S&P Biotech ETF is currently holding 1.52 million shares of worth totaling $23.3 million. The company recently came selling 14640.0 shares which brought its stake up to 3.41% of the company’s outstanding shares. iShares Russell 2000 ETF sold 2430.0 shares, after which its hold over company’s outstanding shares shrunk to 2.06%, leaving 0.92 million shares with the mutual fund that have a worth of about $14.09 million. Biotech Growth Trust Plc, after buying 0.87 million shares, have now control over 1.96% of the stake in the company. It holds 0.0 shares of worth $13.37 million.

However, the stock later moved at a day high price of 26.67, or with a gain of 48.71%. Stock saw a price change of 69.75% in past 5 days and over the past one month there was a price change of 59.68%. Year-to-date (YTD), VERA shares are showing a performance of 64.56% which increased to 176.91% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $5.95 but also hit the highest price of $20.23 during that period. The average intraday trading volume for Vera Therapeutics Inc shares is 586.43K. The stock is currently trading 52.36% above its 20-day simple moving average (SMA20), while that difference is up 68.55% for SMA50 and it goes to 88.69% higher than SMA200.

Woodline Partners LP acquired 2.56 million shares of Vera Therapeutics Inc having value of about $39.41 million. Data submitted at the U.S SEC by Woodline Partners LP revealed that the firm now holds 0.81 million shares in the company valued at close to $20473512.1, or have control over 46.13% stake in the company. Vera Therapeutics Inc (NASDAQ: VERA) currently have 44.43M outstanding shares and institutions hold larger chunk of about 66.16% of that. Holding of mutual funds in the company is about 38.40% while other institutional holders and individual stake holders have control over 48.59% and 27.77% of the stake respectively.

The stock has a current market capitalization of $1.12B and its 3Y-monthly beta is at 0.87. It has posted earnings per share of -$2.87 in the same period. It has Quick Ratio of 6.64 while making debt-to-equity ratio of 0.24. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VERA, volatility over the week remained 12.18% while standing at 9.26% over the month.

Analysts are in expectations that Vera Therapeutics Inc (VERA) stock would likely to be making an EPS of -$0.51 in the current quarter, while forecast for next quarter EPS is -$0.52 and it is -$2.16 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.58 which is -$0.42 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$1.18 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 36.04% while it is estimated to decrease by -1.45% in next year.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Oppenheimer on Jan-26-24 offering an Outperform rating for the stock and assigned a target price of $26 to it.

Most Popular

Related Posts